Main Menu

Video: Drug development and clinical trials for immunotherapy and radiosensitising drugs

Professor Kevin Harrington is Professor of Biological Cancer Therapies and Joint Head of the Division of Radiotherapy and Imaging at the ICR. He works at the forefront of research into biologically targeted agents, and has been a leading figure in phase III clinical trials that have established immunotherapies as approved treatments for melanoma and head and neck cancers.

In the lab, Professor Harrington and his team specialise in developing treatments that use viruses, antibodies or small molecules to selectively destroy cancer cells and activate endogenous anti-tumour activity. They work at the interface between biologically-targeted agents and standard therapies, using new approaches to improve the effectiveness of current treatments.

As Head of the Department for Radiotherapy and Imaging, Professor Harrington has played a leading role in the development of new forms of radiotherapy treatment including Intensity Modulated Radiotherapy (IMRT). He is combining his expertise in radiotherapy and biological therapeutics in the lab by developing radiosensitising agents including targeted drugs.

Professor Harrington has a track record of successful industry partnerships, and is open to approaches for the collaborative development of candidate drugs and agents.

Watch more videos of our researchers

Working with pharmaceutical companies

Dr Marco Gerlinger talking about working with pharmaceutical companies

Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.


New partnerships in cancer epigenetics

Professor Jessica Downs

Our Epigenetics and Genome Stability team, led by Professor Jessica Downs, is working on a variety of research programmes that could be developed in collaboration with commercial partners.


Sharing experience with industry partners

Dr Paul Huang

Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.


Collaborating with commercial partners

Dr Anguraj Sadanandam

Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.


Exploring new opportunities for collaborative working

Professor Uwe Oelfke

Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.


The benefits of partnering with industry

Dr Igor Vivanco

Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.


Connections newsletter

Sign up to our new quarterly newsletter for updates on our Business and Innovation Office and news about working with industry.